The effects of loperamide, or loperamide plus simethicone, on the distribution of gut water as assessed by MRI in a mannitol model of secretory diarrhoea

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 1, 2012, Pages 64-73

  Placidi, E ^a   Marciani, L ^b   Hoad, C L ^a   Napolitano, A ^a,c   Garsed, K C ^b   Pritchard, S E ^a   Cox, E F ^a   Costigan, C ^a   Spiller, R C ^b   Gowland, P A ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LOPERAMIDE; MANNITOL; PLACEBO; SIMETHICONE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; ASCENDING COLON; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TRANSIT; HUMAN; HUMAN EXPERIMENT; MALE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RELAXATION TIME; STOMACH EMPTYING; WATER CONTENT;

ADULT; ANTIDIARRHEALS; ANTIFOAMING AGENTS; BODY WATER; CROSS-OVER STUDIES; DIARRHEA; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL MOTILITY; HUMANS; INTESTINAL ABSORPTION; INTESTINE, SMALL; LOPERAMIDE; MAGNETIC RESONANCE IMAGING; MALE; MANNITOL; MIDDLE AGED; SIMETHICONE; YOUNG ADULT;

EID: 84861801964     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05127.x     Document Type: Article

References (23)

1. Kaplan MA, Prior MJ, Ash RR, McKonly KI, Helzner EC, Nelson EB,. Loperamide-simethicone vs loperamide alone, simethicone alone, and placebo in the treatment of acute diarrhea with gas-related abdominal discomfort. A randomized controlled trial. Arch Fam Med 1999; 8: 243-8.
2. Awouters F, Megens A, Verlinden M, Schuurkes J, Niemegeers C, Janssen PA,. Loperamide. Survey of studies on mechanism of its antidiarrheal activity. Dig Dis Sci 1993; 38: 977-95.
3. Remington M, Fleming CR, Malagelada JR,. Inhibition of postprandial pancreatic and biliary secretion by loperamide in patients with short bowel syndrome. Gut 1982; 23: 98-101.
4. Schiller LR, Ana CAS, Morawski SG, Fordtran JS,. Mechanism of the antidiarrheal effect of loperamide. Gastroenterology 1984; 86: 1475-80.
5. Sandhu BK, Tripp JH, Candy DC, Harries JT,. Loperamide: studies on its mechanism of action. Gut 1981; 22: 658-62.
6. Sandhu BK, Milla PJ, Harries JT,. Mechanisms of action of loperamide. Scand J Gastroenterol Suppl 1983; 84: 85-92.
7. Szilagyi A, Salomon R, Seidman E,. Influence of loperamide on lactose handling and oral-caecal transit time. Aliment Pharmacol Ther 1996; 10: 765-70.
8. Théodorou V, Fioramonti J, Hachet T, Buéno L,. Absorptive and motor components of the antidiarrhoeal action of loperamide: an in vivo study in pigs. Gut 1991; 32: 1355-9.
9. Kachel G, Ruppin H, Hagel J, Barina W, Meinhardt M, Domschke W,. Human intestinal motor activity and transport: effects of a synthetic opiate. Gastroenterology 1986; 90: 85-93.
10. Connor AL, Wray H, Cottrell J, Wilding IR,. A scintigraphic study to investigate the potential for altered gut distribution of loperamide from a loperamide-simethicone formulation in man. Eur J Pharm Sci 2001; 13: 369-74.
11. Read NW,. Al Janabi MN, Bates TE, Barber DC. Effect of gastrointestinal intubation on the passage of a solid meal through the stomach and small intestine in humans. Gastroenterology 1983; 84: 1568-72.
12. Marciani L, Wright J, Foley S, et al,. Effects of a 5-HT3 antagonist, ondansetron, on fasting and postprandial small bowel water content assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2010; 32: 655-63.
13. Hoad CL, Marciani L, Foley S, et al,. Non-invasive quantification of small bowel water content by MRI: a validation study. Phys Med Biol 2007; 52: 6909-22.
14. Marciani L, Cox EF, Hoad CL, et al,. Postprandial changes in small bowel water content in healthy subjects and patients with irritable bowel syndrome. Gastroenterology 2010; 138: 469-77.
15. Basilisco G, Camboni G, Bozzani A, Paravicini M, Bianchi PA,. Oral naloxone antagonizes loperamide-induced delay of orocecal transit. Dig Dis Sci 1987; 32: 829-32.
16. Hoad CL, Cox EF, Gowland PA,. Quantification of T(2) in the abdomen at 3.0 T using a T(2)-prepared balanced turbo field echo sequence. Magn Reson Med 2010; 63: 356-64.
17. Cann PA, Read NW, Holdsworth CD, Barends D,. Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci 1984; 29: 239-47.
18. Yeoh EK, Horowitz M, Russo A, Muecke T, Robb T, Chatterton BE,. Gastrointestinal function in chronic radiation enteritis-effects of loperamide-N-oxide. Gut 1993; 34: 476-82.
19. Fordtran JS, Rector FC Jr, Carter NW,. The mechanisms of sodium absorption in the human small intestine. J Clin Invest 1968; 47: 884-900.
20. Binder HJ, Laurenson JP, Dobbins JW,. Role of opiate receptors in regulation of enkephalin stimulation of active sodium and chloride absorption. Am J Physiol 1984; 247: G432-6.
21. Farack UM, Loeschke K,. Inhibition by loperamide of deoxycholic acid induced intestinal secretion. Naunyn Schmiedebergs Arch Pharmacol 1984; 325: 286-9.
22. Geypens B, Bennink R, Peeters M, et al,. Validation of the lactose-[13C]ureide breath test for determination of orocecal transit time by scintigraphy. J Nucl Med 1999; 40: 1451-5.
23. Rambaud JC, Duprey F, Nouel O, Hostein J, Delpech B, Bernier JJ,. Assessment of the accuracy of segmental perfusion under an occluding balloon for measuring the intrajejunal secretion of albumin and immunoglobulin A. Gut 1981; 22: 371-5.